NCT05703386Recruiting
Imaging the Pathogenesis of Cerebral Small Vessel Disease
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 6 Jan 2023
- Start date
- 8 Nov 2022
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Johns Hopkins University
- Diseases
- Stroke, High blood pressure
- NCT number
- NCT05703386
What you commit to
- Study type: Observational
- Planned participants: 50
- From 8 Nov 2022 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to complete 3 research MRI scans over 1.25 years
Who the study is looking for
- Clinical or radiographic evidence of ischemic stroke
- One vascular risk factor (hypertension, hyperlipidemia, or diabetes)
- Evidence of cerebral small vessel disease on MRI
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kennedy Krieger Institute Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.